CANCER:

Ocular Melanoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Melanoma (1010)

Uveal Melanoma (101)

Cutaneous Melanoma (87)

Mucosal Melanoma (29)

Melanoma (1010)

Uveal Melanoma (101)

Cutaneous Melanoma (87)

Mucosal Melanoma (29)

›

HLA-A*02:01	Uveal Melanoma	HLA-A*02:01	Uveal Melanoma	ipilimumab + tebentafusp Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) ipilimumab + tebentafusp Sensitive : C3 ESMO 2022 - 3wk	ipilimumab + tebentafusp Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks ipilimumab + tebentafusp Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HLA-A*02:01	Uveal Melanoma	HLA-A*02:01	Uveal Melanoma	tebentafusp Sensitive: A1 - Approval tebentafusp Sensitive : A1	tebentafusp Sensitive: A1 - Approval tebentafusp Sensitive : A1
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	TC Sensitive: A2 - Guideline TC Sensitive : A2	TC Sensitive: A2 - Guideline TC Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	ipilimumab Sensitive: A2 - Guideline ipilimumab Sensitive : A2	ipilimumab Sensitive: A2 - Guideline ipilimumab Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
HLA-A2 positive	Uveal Melanoma	HLA-A2 positive	Uveal Melanoma	tebentafusp Sensitive: B - Late Trials tebentafusp Sensitive : B	tebentafusp Sensitive: B - Late Trials tebentafusp Sensitive : B
BRAF V600	Ocular Melanoma	BRAF V600	Ocular Melanoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
BRAF V600	Ocular Melanoma	BRAF V600	Ocular Melanoma	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
BRAF V600E	Ocular Melanoma	BRAF V600E	Ocular Melanoma	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
MBD4 mutation	Uveal Melanoma	MBD4 mutation	Uveal Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
CXCL10 elevation	Uveal Melanoma	CXCL10 elevation	Uveal Melanoma	tebentafusp Sensitive: C3 – Early Trials tebentafusp Sensitive : C3	tebentafusp Sensitive: C3 – Early Trials tebentafusp Sensitive : C3
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	IDE196 Sensitive: C3 – Early Trials IDE196 Sensitive : C3	IDE196 Sensitive: C3 – Early Trials IDE196 Sensitive : C3
LDH-H	Uveal Melanoma	LDH-H	Uveal Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
LDH-H	Uveal Melanoma	LDH-H	Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3
LDH-H	Uveal Melanoma	LDH-H	Uveal Melanoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3

Ocular Melanoma

Associations(105)

Associations
(105)